Stuart F Kushner

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials
    Stuart F Kushner
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ 08560, USA
    Bipolar Disord 8:15-27. 2006
  2. ncbi A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 19:611-21. 2009

Detail Information

Publications2

  1. ncbi Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials
    Stuart F Kushner
    Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ 08560, USA
    Bipolar Disord 8:15-27. 2006
    ..To evaluate the efficacy and tolerability of topiramate monotherapy in adults with acute manic or mixed episodes of bipolar I disorder...
  2. ncbi A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 19:611-21. 2009
    ..The aim of this study was to evaluate the efficacy and safety of two dose ranges of risperidone in adolescents with schizophrenia...